Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer. A review of contributing factors

Clinical Journal of Oncology Nursing

Volumn 12, Issue 3, 2008, Pages 445-454

  Anderson, Nancy J ^a   Hacker, Eileen D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANEMIA; CANCER STAGING; EVIDENCE BASED MEDICINE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MASS SCREENING; MENTAL STRESS; MULTIMODALITY CANCER THERAPY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; ONCOLOGY NURSING; ORGANIZATION AND MANAGEMENT; OVARIECTOMY; OVARY TUMOR; PAIN; REVIEW; RISK FACTOR; SLEEP DISORDER; SURVIVAL RATE;

ANEMIA; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INJECTIONS, INTRAPERITONEAL; MASS SCREENING; NEOPLASM STAGING; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; OVARIAN NEOPLASMS; OVARIECTOMY; PAIN; RISK FACTORS; SLEEP DISORDERS; STRESS, PSYCHOLOGICAL; SURVIVAL RATE;

EID: 49849085054     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.445-454     Document Type: Review

References (74)

1. Aistars, J. (1987). Fatigue in the cancer patient: A conceptual approach to a clinical problem. Oncology Nursing Forum, 14(6), 25-30.
2. Alberts, D.S., Green, S., Hannigan, E.V., O'Toole, R., Stock-Novack, D., Anderson, P., et al. (1992). Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclo-phosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. Journal of Clinical Oncology, 10(5), 706-717.
3. Almadrones, L. (2007). Evidence-based research for Intraperitoneal Chemotherapy in epithelial ovarian cancer. Clinical Journal of Oncology Nursing, 11 (2), 211-216.
4. American Pharmaceutical Partners. (2002). Cisplatin injection [Package insert]. Schaumburg, IL: Author.
5. Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q., Baergen, R., Lele, S., et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354(1), 34-43.
6. Badr, H., Basen-Engquist, K., Carmack Taylor, C.L., & de Moor, C., (2006). Mood states associated with transitory physical symptoms among breast and ovarian cancer survivors. Journal of Behavioal Medicine, 29(5), 461-475.
7. Berger, A.M. (1998). Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncology Nursing Forum, 25(1), 51-62.
8. Berger, A.M., & Higginbotham, P. (2000). Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncology Nursing Forum, 27(9), 1443-1448.
9. Blesch, K.S., Paice, J.A., Wickham, R., Harte, N., Schnoor, D.K., Purl, S., et al. (1991). Correlates of fatigue in people with breast or lung cancer. Oncology Nursing Forum, 18(1), 81-87.
10. Bodurka-Bevers, D., Basen-Engquist, K., Carmack, C.L., Fitzgerald, M.A., Wolf, J.K., de Moor, C., et al. (2000). Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecologic Oncology, 78(3, Pt. 1), 302-308.
11. Bos, A.M., De Vos, F.Y., de Vries, E.G., Beijnen, J.H., Rosing, H., Mourits, M.J., et al. (2005). A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. European Journal of Cancer, 41(4), 539-548.
12. Bower, J.E., Ganz, P.A., Desmond, K.A., Rowland, J.H., Meyerowitz, B.E., & Belin, T.R. (2000). Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18(4), 743-753.
13. Bristol-Myers.S (2003). Taxol (Paclitaxel) for injection. Retrieved March 20, 2007, from http://www.bms.com/cgibin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=19&key+PPI
14. Bristol-Myers.S (2004). Paraplatin (Carboplatin) for injection. Retrieved March 20, 2007, from http://www.bms.com/cgibin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20 where%20PPI_SEQ=15&key=PPI
15. Bristow, R.E., Montz, F.J., Lagasse, L.D., Leuchter, R.S., & Karlan, B.Y. (1999). Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecologic Oncology, 72(3), 278-287.
16. Curt, G.A. (2000). The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist, 5(Suppl. 2), 9-12.
17. Curt, G.A., Breitbart, W., Cella, D., Groopman, J.E., Horning, S.J., Itri, L.M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New fndings from the Fatigue Coalition. Oncologist, 5(5), 353-360.
18. Donovan, H.S., & Ward, S. (2005). Representations of fatigue in women receiving chemotherapy for gynecologic cancers. Oncology Nursing Forum, 32(1), 113-116.
19. Ersek, M., Ferrell, B.R., Dow, K.H., & Melancon, C.H. (1997). Quality of life in women with ovarian cancer. Western Journal of Nursing Research, 19(3), 334-350.
20. Escobar, P.F., Markman, M., Rose, P., Zanotti, K., Webster, K., & Belinson, J. (2004). Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology, 92(1), 192-196.
21. Fox, S.W., & Lyon, D. (2007). Symptom clusters and quality of life in survivors of ovarian cancer. Cancer Nursing, 30(5), 354-361.
22. Francis, P., Rowinsky, E., Schneider, J., Hakes, T., Hoskins, W., & Markman, M. (1995). Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. Journal of Clinical Oncology, 13(12), 2961-2967.
23. Given, B., Given, C., Azzouz, F., & Stommel, M. (2001). Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nursing Research, 50(4), 222-232.
24. Given, B., Given, C., McCorkle, R., Kozachik, S., Cimprich, B., Rahbar, M.H., et al. (2002). Pain and management: Results of a nursing randomized clinical trial. Oncology Nursing Forum, 29(6), 949-956.
25. Glaus, A. (1998). Fatigue in patients with cancer. Analysis and assessment. Recent Results in Cancer Research, 145(IXI), 1-17 2.
26. Hacker, E.D., & Ferrans, C.E. (2003). Quality of life immediately after peripheral blood stem cell transplantation. Cancer Nursing, 26(4), 312-322.
27. Hacker, E.D., Ferrans, C.E., Verlen, E., Ravandi, F., van Besien, K., Gelms, J., et al. (2006). Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. Oncology Nursing Forum, 33(3), 614-624.
28. Harries, M., & Gore, M. (2002). Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncology, 3(9), 529-536.
29. Herben, V.M., Panday, V.R., Richel, D.J., Schellens, J.H., van der Vange, N., Rosing, H., et al. (1999). Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as frst-line therapy in patients with advanced ovarian cancer. Journal of Clinical Oncology, 17(3), 747-755.
30. Holley, S. (2000). Cancer-related fatigue. Suffering a different fatigue. Cancer Practice, 8(2), 87-95.
31. Holzner, B., Kemmler, G., Greil, R., Kopp, M., Zeimet, A., Raderer, M., et al. (2002). The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Annals of Oncology, 13(6), 965-973.
32. Holzner, B., Kemmler, G., Meraner, V., Maislinger, A., Kopp, M., Bodner, T., et al. (2003). Fatigue in ovarian carcinoma patients: a neglected issue? Cancer, 97(6), 1564-1572.
33. Hussain M.M., Kotz H., Miansian L., Premkumar A., Sarosy G., Reed E., et al. (2003). Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. Journal of Clinical Oncology, 21(23), 4356-4363.
34. Irvine, D.M., Vincent, L., Bubela, N., Thompson, L., & Graydon, J. (1991). A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nursing, 14(4), 188-199.
35. Jaaback, K., & Johnson, N. (2006). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2006, 1, CD005340.
36. Jacobsen, P.B., Hann, D.M., Azzarello, L.M., Horton, J., Balducci, L., & Lyman, G.H. (1999). Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. Journal of Pain and Symptom Management, 18(4), 233-242.
37. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58(2), 71-96.
38. Kane, R., Harvey, H., Andrews, T., Bernath, A., Curry, S., Dixon, R., et al. (1979). Phase II trial of cyclophosphamide, hexameth-ylmelamine, adriamycin, and cis-dichlorodiammineplatinum (II) combination chemotherapy in advanced ovarian carcinoma. Cancer Treatment Reports, 63(2), 307-309.
39. Kornblith, A.B., Thaler, H.T., Wong, G., Vlamis, V., Lepore, J. M., Loseth, D.B., et al. (1995). Quality of life of women with ovarian cancer. Gynecologic Oncology, 59(2), 231-242.
40. Lee, K.A. (2001). Sleep and fatigue. Annual Review of Nursing Research, 19, 249-273.
41. Longman, A.J., Braden, C.J., & Mishel, M.H. (1997). Pattern of association over time of side-effects burden, self-help, and self-care in women with breast cancer. Oncology Nursing Forum, 24(9), 1555-1560.
42. Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., et al. (2001). Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19(4), 1001-1007.
43. Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J.L., Jr., et al. (1992). Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 10(9), 1485-1491.
44. Markman, M., Zanotti, K., Webster, K., Peterson, G., Kulp, B., & Belinson, J. (2003). Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecologic Oncology, 91(3), 573-576.
45. McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Look, K.Y., et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334(1), 1-6.
46. Miasowski, C., Cooper, B.A., Paul, S.M., Dodd, M., Lee, K., Aou-jzerat, B.E., et al. (2006). Subgroups of patients with cancer with different symptom experiences and quality of life outcomes: A cluster analysis. Oncology Nursing Forum, 33(5), E79-E89. Retrieved May 6, 2008, from http://ons.metapress.com/content/45j041752130j582/fulltext.pdf
47. Mock, V., Atkinson, A., Barsevick, A., Cella, D., Cimprich, B., Clee-land, C., et al. (2000). NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Huntington), 14(11A), 151-161.
48. Mock, V., Atkinson, A., Barsevick, A., Cella, D., Cimprich, B., Clee-land, C., et al. (2000). NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park), 14(11A), 151-161.
49. Nail, L.M. (2002). Fatigue in patients with cancer. Oncology Nursing Forum, 29(3), 537-546.
50. National Cancer Institute. (2006). Cancer stat fact sheet: Cancer of the ovary. Retrieved July 24, 2007, from http://seer.cancer.gov/ statfacts/html/ovary.html
51. National Cancer Institute. (2006). Clinical announcement: Intraperitoneal chemotherapy for ovarian cancer. Retrieved March 20, 2006, from http://ctep.cancer.gov/highlights/clin annc_010506.pdf
52. National Comprehensive Cancer Network. (2007). NCCN clinical practice guidelines in oncology: Ovarian Cancer. Retrieved July 24, 2007, from http://www.nccn.org/professionals/physi-cian_gls/PDF/ovarian/pdf
53. Norton, T.R., Manne, S.L., Rubin, S., Hernandez, E., Carlson, J., Bergman, C., et al. (2005). Ovarian cancer patients' psychological distress: the role of physical impairment, perceived unsupportive family and friend behaviors, perceived control, and self-esteem. Health Psychology, 24(2), 143-152.
54. Omura, G., Blessing, J.A., Ehrlich, C.E., Miller, A., Yordan, E., Creasman, W.T., et al. (1986). A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer, 57(9), 1725-1730.
55. Omura, G.A., Bundy, B.N., Berek, J.S., Curry, S., Delgado, G., & Mortel, R. (1989). Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 7(4), 457-465.
56. ®: Fatigue detailed PEP cards. Retrieved on July 4, 2007, from http://www.ons.org/outcomes/resources/fatigue.shtml
57. Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Burger, R.A., et al. (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 21(17), 3194-3200.
58. Payne, J.K. (2002). The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy. Oncology Nursing Forum, 29(9), 1334-1340.
59. Pfeife, C.E., Howell, S.B., Markman, M., & Lucas, W.E. (1984). Totally implantable system for peritoneal access. Journal of Clinical Oncology, 2(11), 1277-1280.
60. Pickard-Holley, S. (1991). Fatigue in cancer patients. A descriptive study. Cancer Nursing, 14(1), 13-19.
61. Portenoy, R.K., & Itri, L.M. (1999). Cancer-related fatigue: guidelines for evaluation and management. Oncologist, 4(1), 1-10.
62. Portenoy, R.K., Kornblith, A.B., Wong, G., Vlamis, V., Lepore, J.M., Loseth, D.B., et al. (1994). Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer, 74 (3), 907-915.
63. Rothenberg, M.L., Liu, P.Y., Braly, P.S., Wilczynski, S.P., Hannigan, E.V., Wadler, S., et al. (2003). Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an inter group phase II trial. Journal of Clinical Oncology, 21(7), 1313-1319.
64. Sanofaventis. (2006). Taxotere (docetaxel) injection concentrate. Retrieved March 20, 2007, from http://products.sanof-aventis. us/Taxotere/taxotere.pdf
65. Sura, W., Murphy, S.O., & Gonzales, I. (2006). Level of fatigue in women receiving dose-dense versus standard chemotherapy for breast cancer: A pilot study. Oncology Nursing Forum, 33(5), 1015-1021.
66. Terauchi, F., Hirano, T., Taoka, H., Masaki, K., Yamamoto, Y., Ogura, H., et al. (2003). Weekly docetaxel for patients with platinum/ paclitaxel/irinotecan-resistant relapsed ovarian cancer: A phase I study. International Journal of Clinical Oncology, 8(6), 348-351.
67. Trope, C., & Kaern, J. (2006). Primary surgery for ovarian cancer. European Journal of Surgical Oncology, 32(8), 844-852.
68. van Rijswijk, R.E., Hoekman, K., Burger, C.W., Verheijen, R.H., & Vermorken, J.B. (1997). Experience with intraperitoneal cisplatin and etoposide and IV sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Annals of Oncology, 8 (12), 1235-1241.
69. Vasey, P.A., Jayson, G.C., Gordon, A., Gabra, H., Coleman, R., Atkin-son, R., et al. (2004). Phase III random ized trial of docetaxel-car-boplatin versus paclitaxel-carboplatin as frst-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute, 96(22), 1682-1691.
70. Vogelzang, N.J., Breitbart, W., Cella, D., Curt, G.A., Groopman, J.E., Horning, S.J., et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition. Seminars in Hematology, 34(3, Suppl. 2), 4-12.
71. Walker, J.L., Armstrong, D.K., Huang, H.Q., Fowler, J., Webster, K., Burger, R.A., et al. (2006). Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 100 (1), 27-32.
72. Winningham, M.L., Nail, L.M., Burke, M.B., Brophy, L., Cimprich, B., Jones, L.S., et al. (1994). Fatigue and the cancer experience: The state of the knowledge. Oncology Nursing Forum, 21(1), 23-36.
73. Yen, M.S., Juang, C.M., Lai, C.R., Chao, G.C., Ng, H.T., & Yuan, C.C. (2001). Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. International Journal of Gynaecology and Obstetrics, 72(1), 55-60.
74. Young, R.C., Chabner, B.A., Hubbard, S.P., Fisher, R.I., Bender, R.A., A nderson, T., et al. (1978). Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. New England Journal of Medicine, 299(23), 1261-1266.